Hoth Therapeutics (HOTH) announced that it has received an official Filing Receipt from the United States Patent and Trademark Office for a new patent application related to the proprietary formulation of HT-001, the company’s lead clinical asset. This newly filed application seeks to expand the company’s intellectual property portfolio surrounding HT-001 and builds upon Hoth’s already approved patent for the compound. The formulation-specific filing is aimed at further protecting the unique composition and delivery method of HT-001, which is being developed as a novel topical treatment to alleviate dermatologic side effects commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics announces new patent claim and begins GLP-compliant study
- Hoth Therapeutics announces ‘positive’ results from study of HT-KIT
- Hoth Therapeutics to submit Expanded Access application for HT-001
- Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate
- Hoth Therapeutics’ GDNF shows efficacy in obesity prevention and reversal